Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q66370893 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010735.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q66370893 | ||
| 035 | ‡a (OCoLC)Q66370893 | ||
| 100 | 0 | ‡a Melissa Lingohr-Smith ‡9 en ‡9 ast | |
| 400 | 0 | ‡a Melissa Lingohr-Smith ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States | ||
| 670 | ‡a Author's All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. | ||
| 670 | ‡a Author's An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants | ||
| 670 | ‡a Author's Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. | ||
| 670 | ‡a Author's Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States | ||
| 670 | ‡a Author's Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients | ||
| 670 | ‡a Author's Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients | ||
| 670 | ‡a Author's DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING. | ||
| 670 | ‡a Author's Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation | ||
| 670 | ‡a Author's Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase | ||
| 670 | ‡a Author's Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients | ||
| 670 | ‡a Author's Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results | ||
| 670 | ‡a Author's Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors | ||
| 670 | ‡a Author's Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia | ||
| 670 | ‡a Author's Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States. | ||
| 670 | ‡a Author's Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors | ||
| 670 | ‡a Author's Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States | ||
| 670 | ‡a Author's Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA | ||
| 670 | ‡a Author's Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism? | ||
| 670 | ‡a Author's Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting | ||
| 670 | ‡a Author's Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States | ||
| 670 | ‡a Author's Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. | ||
| 670 | ‡a Author's Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease | ||
| 670 | ‡a Author's The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans | ||
| 670 | ‡a Author's Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States | ||
| 670 | ‡a Author's Update on tolvaptan for the treatment of hyponatremia | ||
| 670 | ‡a Author's Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines | ||
| 670 | ‡a Author's Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States | ||
| 670 | ‡a Author's Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation | ||
| 919 | ‡a comparisonofdifferencesinmedicalcostswhenneworalanticoagulantsareusedforthetreatmentofpatientswithnonvalvularatrialfibrillationandvenousthromboembolismvswarfarinorplacebointheus ‡A Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. ‡9 1 | ||
| 919 | ‡a earlyevaluationofbleedingrelatedhospitalreadmissionsamonghospitalizedpatientswithnonvalvularatrialfibrillationtreatedwithdirectoralanticoagulants ‡A An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants ‡9 1 | ||
| 919 | ‡a reviewofclinicaltrialendpointsofpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionandhowtheyrelatetopatientoutcomesintheunitedstates ‡A A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States ‡9 1 | ||
| 919 | ‡a allcausestrokesystemicembolismandmajorbleedingrelatedhealthcarecostsamongelderlypatientswithnonvalvularatrialfibrillationtreatedwithoralanticoagulants ‡A All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. ‡9 1 | ||
| 919 | ‡a warfarintimeintherapeuticrangeanditsimpactonhealthcareresourceutilizationandcostsamongpatientswithnonvalvularatrialfibrillation ‡A Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation ‡9 1 | ||
| 919 | ‡a usinghealthcareclaimsdatatoassesstheprevalenceofhodgkinlymphomaandrelapsedorrefractoryhodgkinlymphomaintheunitedstates ‡A Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States ‡9 1 | ||
| 919 | ‡a useofrealworldclaimdatabasestoassessprevalenceofcomorbidconditionsrelevanttothetreatmentofchronicmyelogenousleukemiabasedonnationalcomprehensivenetworktreatmentguidelines ‡A Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines ‡9 1 | ||
| 919 | ‡a updateontolvaptanforthetreatmentofhyponatremia ‡A Update on tolvaptan for the treatment of hyponatremia ‡9 1 | ||
| 919 | ‡a treatmentpatternsandantipsychoticmedicationadherenceamongcommerciallyinsuredpatientswithschizoaffectivedisorderintheunitedstates ‡A Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States ‡9 1 | ||
| 919 | ‡a budgetimpactofbrodalumabforthetreatmentofmoderatetosevereplaquepsoriasisonuscommercialhealthplans ‡A The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans ‡9 1 | ||
| 919 | ‡a reducedimagingradiationexposureandcostsassociatedwithantitumornecrosisfactortherapyincrohnsdisease ‡A Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease ‡9 1 | ||
| 919 | ‡a realworldmedicationpersistenceandoutcomesassociatedwithbasalinsulinandglucagonlikepeptide1receptoragonistfreedosecombinationtherapyinpatientswithtype2diabetesintheus ‡A Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. ‡9 1 | ||
| 919 | ‡a realworldmedicalcostavoidancewhenneworalanticoagulantsareusedversuswarfarinforvenousthromboembolismintheunitedstates ‡A Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States ‡9 1 | ||
| 919 | ‡a majorbleedingriskandhealthcareeconomicoutcomesofnonvalvularatrialfibrillationpatientsnewlyinitiatedwithoralanticoagulanttherapyintherealworldsetting ‡A Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting ‡9 1 | ||
| 919 | ‡a isadherencetotheamericancollegeofchestphysiciansrecommendedanticoagulationtreatmentdurationassociatedwithdifferentoutcomesamongpatientswithvenousthromboembolism ‡A Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism? ‡9 1 | ||
| 919 | ‡a influenceofthedurationofhospitallengthofstayonfrequencyofprophylaxisandriskforvenousthromboembolismamongpatientshospitalizedforacutemedicalillnessesintheusa ‡A Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA ‡9 1 | ||
| 919 | ‡a incrementalhealthcareburdenofbleedingamongpatientswithvenousthromboembolismintheunitedstates ‡A Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States ‡9 1 | ||
| 919 | ‡a incrementaleconomicburdenassociatedwithmajorbleedingamongatrialfibrillationpatientstreatedwithfactorxainhibitors ‡A Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors ‡9 1 | ||
| 919 | ‡a impactofwarfarinpersistenceonhealthcareutilizationandcostsamongpatientswithatrialfibrillationmanagedinanticoagulationclinicsintheunitedstates ‡A Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States. ‡9 1 | ||
| 919 | ‡a impactofgeneticmutationsandhealthplanaccesstotherapiesontreatmentresponseanddrugcostsrelatedtotyrosinekinaseinhibitortreatmentamongpatientswithchronicmyelogenousleukemia ‡A Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia ‡9 1 | ||
| 919 | ‡a healthcareandeconomicburdenofadverseeventsamongpatientswithchronicmyelogenousleukemiatreatedwithbcrabl1tyrosinekinaseinhibitors ‡A Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors ‡9 1 | ||
| 919 | ‡a evaluationofmedicalcostsavoidedwhenneworalanticoagulantsareusedforextendedtreatmentofvenousthromboembolismbasedonclinicaltrialresults ‡A Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results ‡9 1 | ||
| 919 | ‡a evaluationofmedicalcostsassociatedwithuseofneworalanticoagulantscomparedwithstandardtherapyamongvenousthromboembolismpatients ‡A Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients ‡9 1 | ||
| 919 | ‡a evaluationofhealthcareresourceutilizationandincrementaleconomicburdenofpatientswithchronicmyeloidleukemiaafterdiseaseprogressiontoblastphase ‡A Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase ‡9 1 | ||
| 919 | ‡a effectofapixabanversuswarfarinuseonhealthcareresourceutilizationandcostsamongelderlypatientswithnonvalvularatrialfibrillation ‡A Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation ‡9 1 | ||
| 919 | ‡a doesclinicalinertiavarybypersonalizeda1cgoalastudyofpredictorsandprevalenceofclinicalinertiainausmanagedcaresetting ‡A DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING. ‡9 1 | ||
| 919 | ‡a correctiontostevendeitelzweigetalcomparisonofeffectivenessandsafetyoftreatmentwithapixabanvsotheroralanticoagulantsamongelderlynonvalvularatrialfibrillationpatients ‡A Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients ‡9 1 | ||
| 919 | ‡a comparisonofeffectivenessandsafetyoftreatmentwithapixabanvsotheroralanticoagulantsamongelderlynonvalvularatrialfibrillationpatients ‡A Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients ‡9 1 | ||
| 919 | ‡a comparisonofdrugswitchinganddiscontinuationratesinpatientswithnonvalvularatrialfibrillationtreatedwithdirectoralanticoagulantsintheunitedstates ‡A Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States ‡9 1 | ||
| 996 | ‡2 NII|DA05094431 | ||
| 996 | ‡2 BIBSYS|90383626 | ||
| 996 | ‡2 RERO|A016603644 | ||
| 996 | ‡2 LC|n 97021916 | ||
| 996 | ‡2 LC|n 2016184933 | ||
| 996 | ‡2 ISNI|0000000029416465 | ||
| 996 | ‡2 LC|n 85359177 | ||
| 996 | ‡2 LC|n 83163851 | ||
| 996 | ‡2 ISNI|0000000383816568 | ||
| 996 | ‡2 J9U|987007346504405171 | ||
| 996 | ‡2 NTA|271577002 | ||
| 996 | ‡2 J9U|987007439619705171 | ||
| 996 | ‡2 LC|no2024136945 | ||
| 996 | ‡2 ISNI|0000000079225966 | ||
| 996 | ‡2 LC|no2017020585 | ||
| 996 | ‡2 LC|no2016122970 | ||
| 996 | ‡2 ISNI|000000002567802X | ||
| 996 | ‡2 CAOONL|ncf11567409 | ||
| 996 | ‡2 SUDOC|229910459 | ||
| 996 | ‡2 LC|n 82047703 | ||
| 996 | ‡2 ISNI|0000000050744199 | ||
| 996 | ‡2 SUDOC|243726791 | ||
| 996 | ‡2 LC|n 87902831 | ||
| 996 | ‡2 LC|nb2023000401 | ||
| 996 | ‡2 NUKAT|n 2007107619 | ||
| 996 | ‡2 CAOONL|ncf11050185 | ||
| 996 | ‡2 LC|n 92009598 | ||
| 996 | ‡2 LC|n 92806495 | ||
| 996 | ‡2 LC|n 2004152520 | ||
| 996 | ‡2 LC|n 2003040737 | ||
| 996 | ‡2 DNB|1115486934 | ||
| 996 | ‡2 RERO|A022958126 | ||
| 996 | ‡2 J9U|987007362232405171 | ||
| 996 | ‡2 J9U|987007350754605171 | ||
| 996 | ‡2 LC|no2023007759 | ||
| 996 | ‡2 ISNI|0000000076310794 | ||
| 996 | ‡2 LC|nr2006009016 | ||
| 996 | ‡2 ISNI|0000000074331647 | ||
| 996 | ‡2 LC|nb2023007450 | ||
| 996 | ‡2 BIBSYS|1592544498748 | ||
| 996 | ‡2 LC|no2009042765 | ||
| 996 | ‡2 NTA|181970597 | ||
| 996 | ‡2 LC|n 2014000202 | ||
| 996 | ‡2 LC|nb2008026054 | ||
| 996 | ‡2 LC|n 87129323 | ||
| 996 | ‡2 CAOONL|ncf11196667 | ||
| 996 | ‡2 LC|no2010048871 | ||
| 996 | ‡2 SUDOC|078135834 | ||
| 996 | ‡2 NLA|000049285675 | ||
| 996 | ‡2 J9U|987007331006905171 | ||
| 996 | ‡2 RERO|A003839665 | ||
| 996 | ‡2 LC|no2011058836 | ||
| 996 | ‡2 ISNI|0000000497865149 | ||
| 996 | ‡2 BNF|16976269 | ||
| 996 | ‡2 LC|n 87101012 | ||
| 996 | ‡2 SUDOC|126608539 | ||
| 996 | ‡2 LC|no2018152035 | ||
| 996 | ‡2 ISNI|0000000425267836 | ||
| 996 | ‡2 ISNI|0000000387646930 | ||
| 996 | ‡2 LC|no 98004579 | ||
| 996 | ‡2 RERO|A003839660 | ||
| 996 | ‡2 ISNI|0000000037108489 | ||
| 996 | ‡2 SUDOC|259270393 | ||
| 996 | ‡2 LC|no2020097561 | ||
| 996 | ‡2 LC|no2021120206 | ||
| 996 | ‡2 LC|no2006026049 | ||
| 996 | ‡2 LC|no 98107513 | ||
| 996 | ‡2 PTBNP|106657 | ||
| 996 | ‡2 CAOONL|ncf10033107 | ||
| 996 | ‡2 ISNI|0000000063624073 | ||
| 996 | ‡2 LC|no2014027441 | ||
| 996 | ‡2 ISNI|0000000080295208 | ||
| 996 | ‡2 LC|no2024066004 | ||
| 996 | ‡2 LC|n 88238165 | ||
| 996 | ‡2 RERO|A003839664 | ||
| 996 | ‡2 BIBSYS|10020233 | ||
| 996 | ‡2 RERO|A003839666 | ||
| 996 | ‡2 RERO|A003839667 | ||
| 996 | ‡2 LC|no2014078897 | ||
| 996 | ‡2 RERO|A025322127 | ||
| 996 | ‡2 ISNI|0000000085305364 | ||
| 996 | ‡2 J9U|987007427973905171 | ||
| 996 | ‡2 CAOONL|ncf11160211 | ||
| 996 | ‡2 LC|n 77004568 | ||
| 996 | ‡2 LC|no2012107719 | ||
| 996 | ‡2 ISNI|0000000033015541 | ||
| 996 | ‡2 LC|n 80046200 | ||
| 996 | ‡2 DNB|1158134770 | ||
| 996 | ‡2 ISNI|0000000077104052 | ||
| 996 | ‡2 RERO|A023068041 | ||
| 996 | ‡2 LC|n 2013042621 | ||
| 996 | ‡2 BIBSYS|7005681 | ||
| 996 | ‡2 ISNI|0000000068377972 | ||
| 996 | ‡2 LC|n 2015010393 | ||
| 996 | ‡2 J9U|987007318582405171 | ||
| 996 | ‡2 ISNI|000000003873940X | ||
| 996 | ‡2 DNB|1067336141 | ||
| 996 | ‡2 LC|no2020120623 | ||
| 996 | ‡2 LC|no 95052676 | ||
| 996 | ‡2 LC|n 89121556 | ||
| 996 | ‡2 LC|nr 93038637 | ||
| 996 | ‡2 J9U|987007300718105171 | ||
| 996 | ‡2 ISNI|0000000024659038 | ||
| 996 | ‡2 LC|nb2021010928 | ||
| 996 | ‡2 LC|no2010100764 | ||
| 996 | ‡2 RERO|A027592343 | ||
| 996 | ‡2 SUDOC|113425716 | ||
| 996 | ‡2 ISNI|0000000048597126 | ||
| 996 | ‡2 ISNI|0000000077637510 | ||
| 996 | ‡2 LC|no2006135732 | ||
| 996 | ‡2 N6I|vtls002563671 | ||
| 996 | ‡2 J9U|987012659667405171 | ||
| 996 | ‡2 ISNI|0000000445110756 | ||
| 996 | ‡2 LC|n 79111477 | ||
| 996 | ‡2 J9U|987007385932005171 | ||
| 996 | ‡2 LC|n 79039115 | ||
| 996 | ‡2 BIBSYS|90299959 | ||
| 996 | ‡2 LC|no2008167221 | ||
| 996 | ‡2 LC|no2015003925 | ||
| 996 | ‡2 BIBSYS|3040180 | ||
| 996 | ‡2 LC|n 2010009462 | ||
| 996 | ‡2 LC|no 89011519 | ||
| 996 | ‡2 ISNI|0000000117561259 | ||
| 996 | ‡2 J9U|987008121673405171 | ||
| 996 | ‡2 JPG|500006663 | ||
| 996 | ‡2 BIBSYS|90273073 | ||
| 996 | ‡2 LC|nb2016013124 | ||
| 996 | ‡2 SUDOC|158906187 | ||
| 996 | ‡2 LC|n 98083541 | ||
| 996 | ‡2 NUKAT|n 2023175284 | ||
| 996 | ‡2 DNB|142373699 | ||
| 996 | ‡2 LC|n 2008029548 | ||
| 996 | ‡2 BIBSYS|90544727 | ||
| 996 | ‡2 BIBSYS|6029826 | ||
| 996 | ‡2 CAOONL|ncf11484043 | ||
| 996 | ‡2 LC|no2015076494 | ||
| 996 | ‡2 DNB|1037575938 | ||
| 996 | ‡2 NTA|071246630 | ||
| 996 | ‡2 ISNI|0000000416668814 | ||
| 996 | ‡2 ISNI|0000000043623196 | ||
| 996 | ‡2 BNCHL|10000000000000000113813 | ||
| 996 | ‡2 ISNI|0000000383826512 | ||
| 996 | ‡2 ISNI|0000000056261841 | ||
| 996 | ‡2 JPG|500055674 | ||
| 996 | ‡2 J9U|987007461193205171 | ||
| 996 | ‡2 LC|nb2023000379 | ||
| 996 | ‡2 J9U|987007441816505171 | ||
| 996 | ‡2 NII|DA05219300 | ||
| 996 | ‡2 DNB|128294228X | ||
| 996 | ‡2 NII|DA04457052 | ||
| 996 | ‡2 LC|no2016130350 | ||
| 996 | ‡2 CAOONL|ncf11187811 | ||
| 996 | ‡2 LC|no2014072207 | ||
| 996 | ‡2 BIBSYS|90862526 | ||
| 996 | ‡2 ISNI|0000000425376215 | ||
| 996 | ‡2 LC|no2014005867 | ||
| 996 | ‡2 ISNI|000000049981429X | ||
| 996 | ‡2 LC|no2018078801 | ||
| 996 | ‡2 ISNI|000000037997706X | ||
| 996 | ‡2 ISNI|000000049628318X | ||
| 996 | ‡2 SUDOC|159807697 | ||
| 996 | ‡2 J9U|987007426941805171 | ||
| 996 | ‡2 ISNI|0000000040083075 | ||
| 996 | ‡2 LC|n 2020058309 | ||
| 996 | ‡2 CAOONL|ncf10054063 | ||
| 996 | ‡2 LC|n 88045113 | ||
| 996 | ‡2 ISNI|0000000022907085 | ||
| 996 | ‡2 ISNI|0000000034083642 | ||
| 996 | ‡2 ISNI|0000000030617264 | ||
| 996 | ‡2 SUDOC|145330184 | ||
| 996 | ‡2 J9U|987007387749605171 | ||
| 996 | ‡2 J9U|987007318026805171 | ||
| 996 | ‡2 KRNLK|KAC200603206 | ||
| 996 | ‡2 CAOONL|ncf11331244 | ||
| 996 | ‡2 ISNI|0000000374594473 | ||
| 996 | ‡2 LC|no2017004893 | ||
| 996 | ‡2 LC|n 86033460 | ||
| 996 | ‡2 LC|no2006046977 | ||
| 996 | ‡2 J9U|987008914538105171 | ||
| 996 | ‡2 ISNI|0000000027561175 | ||
| 996 | ‡2 LC|n 2019013782 | ||
| 996 | ‡2 DNB|103546568X | ||
| 996 | ‡2 ISNI|0000000046823599 | ||
| 996 | ‡2 LC|no2005039699 | ||
| 996 | ‡2 LC|no2010150344 | ||
| 996 | ‡2 J9U|987007406037805171 | ||
| 996 | ‡2 ISNI|0000000373608271 | ||
| 996 | ‡2 ISNI|0000000020348136 | ||
| 996 | ‡2 NLA|000043635826 | ||
| 996 | ‡2 BIBSYS|90299510 | ||
| 996 | ‡2 LC|n 82225400 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
